Catalent to use GPEx cell line tech to make Amarantus' protein candidate
Amarantus BioScience has selected Catalent to make the protein mesencephalic-astrocyte-derived neurotrophic factor (MANF) for its Phase I candidate.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs